Damora Therapeutics Announces 2026 Annual Meeting Results and Election of Directors

Damora Therapeutics, Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. Stockholders elected Michael Landsittel and Cameron Turtle, D.Phil, as Class III members of the Board of Directors to serve until the 2029 Annual Meeting. Additionally, stockholders approved, on an advisory basis, the compensation of the company's named executive officers and voted in favor of holding future advisory votes on executive compensation every year. The selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was also ratified. A total of 55,009,938 shares were represented at the meeting, constituting a quorum. The filing also confirms that the Board has determined to hold future 'Say-on-Pay' votes annually in accordance with the stockholder vote and prior recommendations. No clinical data or regulatory updates were included in this filing.